A multicenter, double-blind, fixed-dose, long-term extension trial of the safety of asenapine using olanzapine as an active control in subjects diagnosed with schizophrenia who completed protocol-P05688.

Trial Profile

A multicenter, double-blind, fixed-dose, long-term extension trial of the safety of asenapine using olanzapine as an active control in subjects diagnosed with schizophrenia who completed protocol-P05688.

Completed
Phase of Trial: Phase III

Latest Information Update: 29 May 2015

At a glance

  • Drugs Asenapine (Primary) ; Olanzapine
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Sponsors Actavis; Forest Laboratories; Merck Sharp & Dohme
  • Most Recent Events

    • 26 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 04 Sep 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 20 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top